Inotiv, Inc. (NOTV): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how new drugs and medical devices make their way from the lab to the market? Inotiv, Inc. (NOTV), a leading contract research organization, plays a crucial role in this process. But how exactly does Inotiv operate, and what makes it a key player in the pharmaceutical and medical device industries? With a 14.3% decrease in revenue for fiscal year 2024, totaling $490.7 million, let's delve into the history, ownership, mission, operational model, and revenue streams of this company to understand its significance in the drug development ecosystem.

Inotiv, Inc. (NOTV) History

Inotiv's Founding Timeline

Year established

The company was initially established in 1994.

Original location

The original location is West Lafayette, Indiana.

Founding team members

The details of the founding team members are not widely available in the provided search results.

Initial capital/funding

Details regarding the initial capital or funding for the company's establishment are not available in the provided search results.

Inotiv's Evolution Milestones

Inotiv's Transformative Moments

• Strategic Acquisitions: The company has grown significantly through strategic acquisitions. For example, the acquisition of Bioanalytical Research Corporation (BARC) in 2018 expanded its service offerings into large molecule bioanalysis. Similarly, the acquisition of Plato BioPharma, Inc. in 2019 enhanced capabilities in cardiovascular, renal, and pulmonary research models.
• Focus on Specialization: The company has strategically focused on bioanalytical and toxicology services.
• Financial Restructuring and Leadership Changes: In 2023, facing financial headwinds, the company underwent significant restructuring, including a change in CEO with Robert Leasure Jr. stepping in to navigate these challenges. These changes reflect a pivotal moment in the company's efforts to stabilize and realign its strategic priorities.
• Divestiture of RMS Business: In 2022, the company divested its Research Model and Services (RMS) business to Envigo RMS Holding Corp. for approximately $53.5 million. This decision was aimed at simplifying the business model, reducing operational complexity, and allowing greater focus on the higher-growth Discovery and Safety Assessment segments.

For insights into the company's financial health, you might find this resource helpful: Breaking Down Inotiv, Inc. (NOTV) Financial Health: Key Insights for Investors

Inotiv, Inc. (NOTV) Ownership Structure

Understanding Inotiv's ownership structure provides key insights into its governance and strategic direction. A mix of institutional and individual investors currently holds the majority of the company's shares.

Inotiv, Inc.'s Current Status

Inotiv, Inc. is a public company, trading on the Nasdaq Stock Market under the ticker symbol NOTV. This means that ownership is distributed among public shareholders, who can freely trade shares of the company.

Inotiv, Inc.'s Ownership Breakdown

The ownership of Inotiv is distributed among various types of shareholders, including institutional investors, individual shareholders, and company insiders. The following table summarizes the ownership breakdown:

Inotiv, Inc.'s Leadership

Inotiv's leadership team is responsible for the strategic direction and operational management of the company. Key members of the leadership team as of April 2025 include:

• Robert Leasure, Jr. serves as the President and Chief Executive Officer.
• Beth A. Roberts holds the position of Chief Financial Officer.
• John E. Sagartz is the Chief Strategy Officer.

These individuals, along with other key executives and board members, guide Inotiv's strategy and operations in the competitive pharmaceutical and biotechnology services market. For more in-depth insights into Inotiv's investor profile, you might find this resource helpful: Exploring Inotiv, Inc. (NOTV) Investor Profile: Who’s Buying and Why?

Inotiv, Inc. (NOTV) Mission and Values

The company's mission is to help its clients accelerate drug discovery and development, and its core values include integrity, scientific excellence, and a commitment to customer service. Mission Statement, Vision, & Core Values of Inotiv, Inc. (NOTV).

Inotiv, Inc.'s Core Purpose

Official mission statement

The mission statement is: 'To help our clients accelerate drug discovery and development.'

• Inotiv aims to assist pharmaceutical, biotechnology, and academic clients in bringing new and improved medicines to market more efficiently.
• The company focuses on providing comprehensive services and products that span the drug development pipeline.
• By focusing on speed and efficiency, Inotiv seeks to reduce the time and cost associated with drug development.

Vision statement

The vision statement is not explicitly provided in the search results. However, based on Inotiv's activities and focus, an inferred vision could be:

• To be a leading provider of drug discovery and development solutions.
• To drive innovation and improve outcomes in the pharmaceutical and biotechnology industries.
• To expand capabilities and global reach to better serve clients' evolving needs.

Company slogan/tagline

The company's slogan or tagline is not explicitly stated in the provided search results. Without a specific tagline, it's challenging to define a concrete slogan used by the company.

Inotiv, Inc. (NOTV) How It Works

Inotiv, Inc. provides contract research services and analytical instruments to pharmaceutical, chemical, and biotechnology companies, supporting drug discovery and development.

Inotiv, Inc.'s Product/Service Portfolio

Inotiv, Inc.'s Operational Framework

Inotiv operates through two main segments:

• Discovery and Safety Assessment (DSA): This segment focuses on providing comprehensive preclinical services, from initial discovery to safety assessment, helping clients identify and develop promising drug candidates. These services include:
  • In vitro and in vivo studies
  • Pharmacology and toxicology testing
  • Drug metabolism and pharmacokinetic (DMPK) analysis
• Research Models and Services (RMS): This segment specializes in producing and distributing research models, including genetically modified animals, and offering related services to support research institutions and pharmaceutical companies. This includes:
  • Breeding and supplying specialized animal models
  • Genetic testing and biobanking
  • Model characterization and consulting

Inotiv's operational framework is designed to provide integrated solutions to its clients, combining preclinical services with research models to accelerate drug discovery and development. They leverage their scientific expertise, advanced technologies, and quality systems to ensure reliable and reproducible results.

For more insights into Inotiv, Inc., check out: Exploring Inotiv, Inc. (NOTV) Investor Profile: Who’s Buying and Why?

Inotiv, Inc.'s Strategic Advantages

• Comprehensive Service Portfolio: Inotiv offers a wide range of services from early discovery to safety assessment, providing clients with integrated solutions.
• Specialized Research Models: They produce and supply specialized animal models, which are essential for preclinical research.
• Scientific Expertise: Inotiv employs experienced scientists and technical staff, ensuring high-quality research and reliable results.
• Advanced Technologies: They utilize state-of-the-art equipment and technologies to enhance the accuracy and efficiency of their services.
• Strategic Acquisitions: Inotiv has grown through strategic acquisitions, expanding its service offerings and geographic reach.

Inotiv, Inc. (NOTV) How It Makes Money

Inotiv, Inc. generates revenue by providing drug discovery and development services as well as research models and services to the pharmaceutical, biotechnology, and academic sectors.

Inotiv, Inc.'s Revenue Breakdown

While specific percentage breakdowns for 2024 aren't available in the provided search results, Inotiv's revenue is generally derived from two main segments:

Inotiv, Inc.'s Business Economics

Inotiv's business economics are driven by several factors:

• Service Pricing: Inotiv employs a project-based pricing model for its discovery and development services, with fees varying based on the complexity and duration of each project.
• Research Model Pricing: Pricing for research models depends on the species, strain, and quantity ordered, with premium models commanding higher prices.
• Market Demand: The overall demand for drug discovery and development services, influenced by pharmaceutical and biotechnology R&D spending, significantly impacts Inotiv's revenue.
• Acquisitions: Strategic acquisitions, such as the acquisition of Integrated Pharma Services (IPS), have expanded Inotiv's service offerings and revenue streams.
• Operational Efficiency: Maintaining efficient operations and managing costs are crucial for profitability.

Inotiv, Inc.'s Financial Performance

Key aspects of Inotiv's financial performance include:

• Revenue Growth: Inotiv has demonstrated substantial revenue growth through a combination of organic expansion and strategic acquisitions. For instance, the acquisition of Integrated Pharma Services (IPS) was projected to add approximately $22 million in annualized revenue.
• Gross Profit Margin: Inotiv's gross profit margin reflects its ability to control the costs associated with its services and research models.
• Operating Expenses: Operating expenses include research and development costs, sales and marketing expenses, and administrative costs.
• Net Income/Loss: Net income or loss reflects Inotiv's overall profitability after accounting for all revenues and expenses.
• Cash Flow: Monitoring cash flow from operations, investing, and financing activities is essential for assessing Inotiv's financial health.
• Breaking Down Inotiv, Inc. (NOTV) Financial Health: Key Insights for Investors

Inotiv, Inc. (NOTV) Market Position & Future Outlook

Inotiv, Inc. is strategically positioned in the pre-clinical research services market, with a focus on drug discovery and development support. The company's future outlook hinges on its ability to capitalize on the growing demand for outsourced research services and its capacity to integrate and leverage recent acquisitions.

Competitive Landscape

Opportunities & Challenges

Industry Position

Inotiv holds a significant position within the pre-clinical research services industry, focusing on providing comprehensive solutions to pharmaceutical and biotechnology companies. The company's standing is characterized by:

• Niche Expertise: Specialization in areas like toxicology, pharmacology, and bioanalysis.
• Integrated Services: Offering a suite of services from early discovery to IND-enabling studies.
• Strategic Acquisitions: Expanding capabilities and market reach through targeted acquisitions.

To delve deeper into the company's core principles, explore: Mission Statement, Vision, & Core Values of Inotiv, Inc. (NOTV).